Primary Site >> Liver Cancer

Gene >> RET

Journal: Curr Drug Targets. 2001 Mar;2(1):41-55.
Title: Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene.
Author: Longati, P|Comoglio, P M|Bardelli, A
PMID: 11465538
Journal: Cancer Res. 2006 Dec 15;66(24):11851-8.
Title: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Author: Liu, Li|Cao, Yichen|Chen, Charles|Zhang, Xiaomei|McNabola, Angela|Wilkie, Dean|Wilhelm, Scott|Lynch, Mark|Carter, Christopher
PMID: 17178882
Journal: Eur J Med Res. 2011 Nov 10;16(11):491-4.
Title: Sunitinib induced pyoderma gangrenosum-like ulcerations.
Author: Akanay-Diesel, S|Hoff, N P|Kurle, S|Haes, J|Erhardt, A|Haussinger, D|Schulte, K-W|Bolke, Edwin|Matuschek, C|Budach, W|Gerber, P A|Homey, B
PMID: 22027642
Journal: Exp Ther Med. 2011 May;2(3):399-403.
Title: Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinoma.
Author: Liu, Shi|Gong, Jian|Morishita, Asahiro|Nomura, Takako|Miyoshi, Hisaaki|Tani, Joji|Kato, Kiyohito|Yoneyama, Hirohito|Deguchi, Akihiro|Mori, Hirohito|Mimura, Shima|Nomura, Kei|Himoto, Takashi|Deguchi, Kazushi|Okano, Keiichi|Izuishi, Kunihiko|Suzuki, Yasuyuk
PMID: 22977516
Journal: Curr Med Chem. 2012;19(7):938-44.
Title: Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.
Author: Ranieri, G|Gadaleta-Caldarola, G|Goffredo, V|Patruno, R|Mangia, A|Rizzo, A|Sciorsci, R L|Gadaleta, C D
PMID: 22214462
Journal: J Nucl Med. 2012 Sep;53(9):1352-8.
Title: Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET.
Author: Rischke, H Christian|Benz, Matthias R|Wild, Damian|Mix, Michael|Dumont, Rebecca A|Campbell, Dean|Seufert, Jochen|Wiech, Thorsten|Rossler, Jochen|Weber, Wolfgang A|Neumann, Hartmut P H
PMID: 22836345
Journal: Invest New Drugs. 2013 Aug;31(4):1078-86.
Title: Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.
Author: Belum, Viswanath Reddy|Wu, Shenhong|Lacouture, Mario E
PMID: 23700287
Journal: J Magn Reson Imaging. 2013 Sep;38(3):548-54.
Title: Timing of the hepatic arterial phase at Gd-EOB-DTPA-enhanced hepatic dynamic MRI: comparison of the test-injection and the fixed-time delay method.
Author: Nakamura, Shinichi|Nakaura, Takeshi|Kidoh, Masafumi|Utsunomiya, Daisuke|Doi, Yasuro|Harada, Kazunori|Uemura, Shozaburou|Yamashita, Yasuyuki
PMID: 23744782
Journal: BioDrugs. 2013 Dec;27(6):615-28.
Title: Sorafenib and thyroid cancer.
Author: Fallahi, Poupak|Ferrari, Silvia Martina|Santini, Francesca|Corrado, Alda|Materazzi, Gabriele|Ulisse, Salvatore|Miccoli, Paolo|Antonelli, Alessandro
PMID: 23818056
Journal: Cancer Chemother Pharmacol. 2013 Dec;72(6):1183-93.
Title: Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis.
Author: Bousquet, Guilhem|Varna, Mariana|Ferreira, Irmine|Wang, Li|Mongiat-Artus, Pierre|Leboeuf, Christophe|de Bazelaire, Cedric|Faivre, Sandrine|Bertheau, Philippe|Raymond, Eric|Germain, Stephane|Janin, Anne
PMID: 24061866
Journal: J Carcinog. 2013 Dec 31;12:22.
Title: Targeted therapies in development for non-small cell lung cancer.
Author: Reungwetwattana, Thanyanan|Dy, Grace Kho
PMID: 24574860
Journal: Recent Results Cancer Res. 2014;201:185-96.
Title: Regorafenib.
Author: Ettrich, Thomas J|Seufferlein, Thomas
PMID: 24756792
Journal: PLoS One. 2014 May 5;9(5):e96799.
Title: Harnessing high density lipoproteins to block transforming growth factor beta and to inhibit the growth of liver tumor metastases.
Author: Medina-Echeverz, Jose|Fioravanti, Jessica|Diaz-Valdes, Nancy|Frank, Kathrin|Aranda, Fernando|Gomar, Celia|Ardaiz, Nuria|Dotor, Javier|Umansky, Viktor|Prieto, Jesus|Berraondo, Pedro
PMID: 24797128
Journal: Vasc Cell. 2014 Sep 6;6:18.
Title: Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage.
Author: Yamamoto, Yuji|Matsui, Junji|Matsushima, Tomohiro|Obaishi, Hiroshi|Miyazaki, Kazuki|Nakamura, Katsuji|Tohyama, Osamu|Semba, Taro|Yamaguchi, Atsumi|Hoshi, Sachi Suzuki|Mimura, Fusayo|Haneda, Toru|Fukuda, Yoshio|Kamata, Jun-Ichi|Takahashi, Keiko|Matsukura,
PMID: 25197551
Journal: Onco Targets Ther. 2015 Dec 8;8:3691-701.
Title: Profile of nintedanib in the treatment of solid tumors: the evidence to date.
Author: Awasthi, Niranjan|Schwarz, Roderich E
PMID: 26677336
Journal: Anticancer Drugs. 2015 Oct;26(9):1004-7.
Title: A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.
Author: Sereno, Maria|Moreno, Victor|Moreno Rubio, Juan|Gomez-Raposo, Cesar|Garcia Sanchez, Sagrario|Hernandez Jusdado, Rebeca|Falagan, Sandra|Zambrana Tebar, Francisco|Casado Saenz, Enrique
PMID: 26237499
Journal: J Nucl Med. 2015 Jun;56(6):839-46.
Title: Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
Author: van Berkel, Anouk|Rao, Jyotsna U|Lenders, Jacques W M|Pellegata, Natalia S|Kusters, Benno|Piscaer, Ianthe|Hermus, Ad R M M|Plantinga, Theo S|Langenhuijsen, Johan F|Vriens, Dennis|Janssen, Marcel J R|Gotthardt, Martin|Timmers, Henri J L M
PMID: 25883126
Journal: Drugs. 2015 Apr;75(5):553-60.
Title: Lenvatinib: first global approval.
Author: Scott, Lesley J
PMID: 25795101
Journal: Tumour Biol. 2015 Mar;36(3):1511-8.
Title: Overexpression of miR-218 inhibits hepatocellular carcinoma cell growth through RET.
Author: Sui, Chengjun|Xu, Feng|Shen, Weifeng|Geng, Li|Xie, Feng|Dai, Binghua|Lu, Jiongjiong|Zhang, Minfeng|Yang, Jiamei
PMID: 25374061
Journal: Oncotarget. 2016 Jun 14;7(24):36829-36841.
Title: GDNF secreted from adipose-derived stem cells stimulates VEGF-independent angiogenesis.
Author: Zhong, Zhaohui|Gu, Huiying|Peng, Jirun|Wang, Wenzheng|Johnstone, Brian H|March, Keith L|Farlow, Martin R|Du, Yansheng
PMID: 27167204
Journal: J Gastroenterol. 2017 Apr;52(4):512-519.
Title: Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Author: Ikeda, Kenji|Kudo, Masatoshi|Kawazoe, Seiji|Osaki, Yukio|Ikeda, Masafumi|Okusaka, Takuji|Tamai, Toshiyuki|Suzuki, Takuya|Hisai, Takashi|Hayato, Seiichi|Okita, Kiwamu|Kumada, Hiromitsu
PMID: 27704266
Journal: Theranostics. 2017 Jan 1;7(1):164-179.
Title: Smart Cu(II)-aptamer complexes based gold nanoplatform for tumor micro-environment triggered programmable intracellular prodrug release, photodynamic treatment and aggregation induced photothermal therapy of hepatocellular carcinoma.
Author: Zhang, Da|Zheng, Aixian|Li, Juan|Wu, Ming|Wu, Lingjie|Wei, Zuwu|Liao, Naishun|Zhang, Xiaolong|Cai, Zhixiong|Yang, Huanghao|Liu, Gang|Liu, Xiaolong|Liu, Jingfeng
PMID: 28042325
Journal: Eur J Drug Metab Pharmacokinet. 2017 Dec;42(6):903-914.
Title: Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor.
Author: Hussein, Ziad|Mizuo, Hitoshi|Hayato, Seiichi|Namiki, Masayuki|Shumaker, Robert
PMID: 28236116
Journal: Oncol Rep. 2017 Apr;37(4):2215-2226.
Title: TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.
Author: Ye, Song|Zhao, Xin-Yi|Hu, Xiao-Ge|Li, Tang|Xu, Qiu-Ran|Yang, Huan-Ming|Huang, Dong-Sheng|Yang, Liu
PMID: 28350084
Journal: Oncotarget. 2017 Apr 18;8(16):26434-26447.
Title: RAB10 overexpression promotes tumor growth and indicates poor prognosis of hepatocellular carcinoma.
Author: Wang, Wei|Jia, Wei-Dong|Hu, Bing|Pan, Yue-Yin
PMID: 28460436
Journal: Future Oncol. 2017 Jul 13.
Title: Cabozantinib in the treatment of hepatocellular carcinoma.
Author: B Peters, Mary Linton|Miksad, Rebecca A
PMID: 28703624
Journal: Eur J Cancer. 2017 Nov;86:296-304.
Title: Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.
Author: Schoffski, Patrick|Gordon, Michael|Smith, David C|Kurzrock, Razelle|Daud, Adil|Vogelzang, Nicholas J|Lee, Yihua|Scheffold, Christian|Shapiro, Geoffrey I
PMID: 29059635
Journal: Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):278-282.
Title: Quantitative (18)F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype.
Author: Amodru, Vincent|Guerin, Carole|Delcourt, Sarkis|Romanet, Pauline|Loundou, Anderson|Viana, Bruna|Brue, Thierry|Castinetti, Frederic|Sebag, Frederic|Pacak, Karel|Taieb, David
PMID: 28918451
Journal: Lancet. 2018 Mar 24;391(10126):1163-1173.
Title: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Author: Kudo, Masatoshi|Finn, Richard S|Qin, Shukui|Han, Kwang-Hyub|Ikeda, Kenji|Piscaglia, Fabio|Baron, Ari|Park, Joong-Won|Han, Guohong|Jassem, Jacek|Blanc, Jean Frederic|Vogel, Arndt|Komov, Dmitry|Evans, T R Jeffry|Lopez, Carlos|Dutcus, Corina|Guo, Matthew|Sai
PMID: 29433850
Journal: Recent Results Cancer Res. 2018;211:45-56.
Title: Regorafenib.
Author: Ettrich, Thomas J|Seufferlein, Thomas
PMID: 30069758
Journal: Recent Results Cancer Res. 2018;211:187-198.
Title: Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRalpha, KIT and RET.
Author: Zschabitz, Stefanie|Grullich, Carsten
PMID: 30069768
Journal: Expert Rev Anticancer Ther. 2018 Sep 15:1-8.
Title: Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
Author: Spallanzani, Andrea|Orsi, Giulia|Andrikou, Kalliopi|Gelsomino, Fabio|Rimini, Margherita|Riggi, Laura|Cascinu, Stefano
PMID: 30220234